What is the name of the vaccine against ticks for humans? - briefly
No vaccine specifically prevents tick bites in humans; only vaccines exist for certain tick‑borne diseases, such as tick‑borne encephalitis.
What is the name of the vaccine against ticks for humans? - in detail
The only human vaccine that specifically targeted a tick‑borne pathogen was Lymerix, a recombinant OspA vaccine against Lyme disease. It received FDA approval in 1998, was withdrawn from the market in 2002 due to low demand and concerns about adverse events, and is no longer available.
Current development focuses on next‑generation Lyme disease vaccines:
- VLA15 (Valneva) – a multivalent OspA formulation covering six Borrelia species; Phase III trials completed, regulatory review ongoing in the United States and Europe.
- IXIARO (formerly JEVAX) – a Japanese encephalitis vaccine that also provides limited cross‑protection against certain tick‑borne flaviviruses; approved for adult use in several countries.
- Tick‑bite prevention immunotherapies – experimental vaccines targeting tick salivary proteins (e.g., Salp15) to block pathogen transmission; pre‑clinical studies demonstrate reduced infection rates in animal models.
No vaccine has been licensed specifically for preventing tick attachment or the full spectrum of tick‑borne diseases in humans. Existing prophylactic measures rely on personal protection, environmental management, and prompt removal of attached ticks.